Physician profile
Eng Kock C Tan
NPI 1932236064
$7,421.37
in general payments reported to CMS, 2019-2025
13 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $582 · 2021: $696 · 2022: $1,028 · 2023: $1,202 · 2024: $1,315 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,074.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,820.65 | 2020-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,162.54 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $1,158.38 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $867.02 | 2019-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $807.40 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Allergan, INC. | $402.36 | 2019-2020 | |
| Indivior INC. | $306.78 | 2019-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $296.68 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $188.02 | 2023-2024 | Fanapt, Hetlioz |
| Abbvie INC. | $138.26 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $110.75 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.69 | 2022 | |
| Noven Therapeutics, LLC | $74.84 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eng Kock Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.